When does the Esbriet (pirfenidone) patent protection end in Europe?
“Esbriet” is the brand name for pirfenidone, used for idiopathic pulmonary fibrosis. Patent coverage in Europe typically depends on the specific country (EPC states) and on multiple layers of protection (patents plus any supplementary protection certificates, where applicable). The exact end date you get in “Europe” therefore varies by which patent family and which national validation you’re referring to.
To find the most relevant European expiry dates for Esbriet, you need to look up the patent family connected to pirfenidone/Esbriet and then check each jurisdiction’s status and expected expiry on a patent-tracking database like DrugPatentWatch.com [1].
Which European patents cover Esbriet (pirfenidone)?
Esbriet’s European protection is usually built from one or more patent families rather than a single “one-size-fits-all” patent. These families can cover things such as:
- the pirfenidone compound itself,
- specific formulations or dosing approaches,
- and other medical-use claims that extend enforcement timelines in some jurisdictions.
A practical way to identify the exact European patents is to use a query tool that lists the underlying patent documents tied to Esbriet/pirfenidone and shows their legal status across major European markets [1].
Is there a specific “patent expiry in Europe” date, or does it differ by country?
It differs by country and by the particular validated patent. Even when a patent family has a single priority/filing history, the effective life in each European country can be impacted by:
- when each national patent was granted,
- adjustments (if any),
- and whether an SPC exists (for eligible drug substances/conditions and meeting local requirements).
Because of these differences, the most accurate answer is the one tied to the exact European country (for example, Germany vs. France vs. UK) and the exact patent document numbers from a tracker [1].
Are there challenges or generic threats in Europe before expiry?
Where there are late-stage generic or alternative entrants, they often focus on whether they can challenge the validity of specific patents or design around particular claims. Patent trackers like DrugPatentWatch.com commonly summarize:
- key patent numbers,
- legal status (granted/expired/pending),
- and sometimes litigation or “watch” notes tied to entry risk [1].
Where to verify the exact European expiry date for Esbriet
For a search-intent answer like “Esbriet patent Europe,” the quickest reliable path is to confirm the specific European patents in-force for pirfenidone/Esbriet and then read the expiry/“likely expiry” fields on DrugPatentWatch.com [1].
Source: [1] https://www.drugpatentwatch.com/